Idiopathic Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension: Can We Be Certain?

被引:0
作者
Berger, Gidon [1 ,2 ]
Azzam, Zaher S. [2 ,3 ,4 ]
Hardak, Emilia [1 ]
Tavor, Yonit [2 ]
Yigla, Mordechai [1 ,4 ]
机构
[1] Rambam Hlth Care Campus, Div Pulm, IL-31096 Haifa, Israel
[2] Rambam Hlth Care Campus, Dept Internal Med B, IL-31096 Haifa, Israel
[3] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Haifa, Israel
[4] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel
来源
ISRAEL MEDICAL ASSOCIATION JOURNAL | 2011年 / 13卷 / 02期
关键词
pulmonary small-vessel disease; pulmonary large-vessel disease; idiopathic pulmonary arterial hypertension (IPAH); chronic thromboembolic pulmonary hypertension (CTEPH); thrombosis; pulmonary embolism; anticoagulation; BOSENTAN THERAPY; LESIONS; GENE; THROMBOENDARTERECTOMY; ANTICOAGULATION; EPOPROSTENOL; MUTATIONS; EMBOLISM; DISEASE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idiopathic pulmonary arterial hypertension (IPAH) is an isolated small-vessel disease comprising vasoconstriction, remodeling and thrombosis of small pulmonary arteries. However, there is evidence that IPAH does not respect anatomic boundaries and might extend into large vessels such as large central thrombi. On the other hand, chronic thromboembolic pulmonary hypertension (CTEPH) represents a distinct category of pulmonary hypertension as it is thought to be due to an occlusion of the major pulmonary arteries following a thromboembolic event. However, it is currently evident that in most patients there is a concomitant small-vessel disease. The involvement of both small and large vessels in both IPAH and CTEPH, together with a high incidence of silent thromboembolic events, might create difficulties in identifying the true cause of pulmonary hypertension. An accurate diagnosis of the cause determines the management and prognosis. Patients with CTEPH can potentially be offered curative surgery in the form of pulmonary endarterectomy; however, oxygen, vasodilators, anticoagulation, and lung transplantation are more feasible options for IPAH. IMAJ 2011; 13:106-110
引用
收藏
页码:106 / 110
页数:5
相关论文
共 39 条
[1]   Plaque composition in plexogenic and thromboembolic pulmonary hypertension:: the critical role of thrombotic material in pultaceous core formation [J].
Arbustini, E ;
Morbini, P ;
D'Armini, AM ;
Repetto, A ;
Minzioni, G ;
Piovella, F ;
Viganò, M ;
Tavazzi, L .
HEART, 2002, 88 (02) :177-182
[2]   Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension [J].
Bauer, M ;
Wilkens, HC ;
Langer, F ;
Schneider, SO ;
Lausberg, H ;
Schäfers, HJ .
CIRCULATION, 2002, 105 (09) :1034-1036
[3]   Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism [J].
Becattini, Cecilia ;
Agnelli, Giancarlo ;
Pesavento, Raffaele ;
Silingardi, Mauro ;
Poggio, Renzo ;
Taliani, Maria Rita ;
Ageno, Walter .
CHEST, 2006, 130 (01) :172-175
[4]  
Berger G, 2009, ISR MED ASSOC J, V11, P376
[5]   PRIMARY PULMONARY-HYPERTENSION - A HISTOPATHOLOGIC STUDY OF 80 CASES [J].
BJORNSSON, J ;
EDWARDS, WD .
MAYO CLINIC PROCEEDINGS, 1985, 60 (01) :16-25
[6]  
Bonderman D, 2005, CHEST, V128, P2599, DOI 10.1378/chest.128.4.2599
[7]   Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension [J].
Bresser, P ;
Fedullo, PF ;
Auger, WR ;
Channick, RN ;
Robbins, IM ;
Kerr, KM ;
Jamieson, SW ;
Rubin, LJ .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) :595-600
[8]   THE CLINICAL COURSE OF PULMONARY-EMBOLISM [J].
CARSON, JL ;
KELLEY, MA ;
DUFF, A ;
WEG, JG ;
FULKERSON, WJ ;
PALEVSKY, HI ;
SCHWARTZ, JS ;
THOMPSON, BT ;
POPOVICH, J ;
HOBBINS, TE ;
SPERA, MA ;
ALAVI, A ;
TERRIN, ML .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (19) :1240-1245
[9]   Chronic thromboembolic pulmonary hypertension [J].
Dartevelle, P ;
Fadel, E ;
Mussot, S ;
Chapelier, A ;
Hervé, P ;
de Perrot, M ;
Cerrina, J ;
Ladurie, FL ;
Lehouerou, D ;
Humbert, M ;
Sitbon, O ;
Simonneau, G .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) :637-648
[10]   Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene [J].
Deng, ZM ;
Morse, JH ;
Slager, SL ;
Cuervo, N ;
Moore, KJ ;
Venetos, G ;
Kalachikov, S ;
Cayanis, E ;
Fischer, SG ;
Barst, RJ ;
Hodge, SE ;
Knowles, JA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (03) :737-744